https://edgen.dev.edgen.tech/news/post/bitcoin-tops-80000-as-treasury-buyback-plan-revives-debasement-trade2026-08-28T13:33:46.733Zdaily1Edgen Stocken2026-08-28T13:33:46.733+00:00Bitcoin tops $80,000 as Treasury buyback plan revives debasement tradehttps://static.edwealth.ai/news/images/bitcoin-tops-80000-as-treasury-buyback-plan-revives-debasement-trade-20260828.pngBitcoin tops $80,000 as Treasury buyback plan revives debasement trade https://edgen.dev.edgen.tech/news/post/cxmt-recoups-5-billion-in-one-quarter-on-ai-memory-demand2026-08-28T13:30:42.222Zdaily1Edgen Stocken2026-08-28T13:30:42.222+00:00CXMT recoups $5 billion in one quarter on AI memory demandhttps://static.edwealth.ai/news/images/cxmt-recoups-5-billion-in-one-quarter-on-ai-memory-demand-20260828.pngCXMT recoups $5 billion in one quarter on AI memory demand https://edgen.dev.edgen.tech/news/post/four-retirement-traps-emerge-once-portfolios-hit-2-million2026-08-28T13:29:16.678Zdaily1Edgen Stocken2026-08-28T13:29:16.678+00:00Four Retirement Traps Emerge Once Portfolios Hit $2 Millionhttps://static.edwealth.ai/news/images/four-retirement-traps-emerge-once-portfolios-hit-2-million-20260828.pngFour Retirement Traps Emerge Once Portfolios Hit $2 Million https://edgen.dev.edgen.tech/news/post/anthropic-abandons-7-billion-matx-deal-presses-in-house-chip-push2026-08-28T13:28:39.659Zdaily1Edgen Stocken2026-08-28T13:28:39.659+00:00Anthropic abandons $7 billion MatX deal, presses in-house chip pushhttps://static.edwealth.ai/news/images/anthropic-abandons-7-billion-matx-deal-presses-in-house-chip-push-20260828.pngAnthropic abandons $7 billion MatX deal, presses in-house chip push https://edgen.dev.edgen.tech/news/post/france-spain-inflation-surge-fully-prices-ecb-september-25bp-hike2026-08-28T13:26:53.777Zdaily1Edgen Stocken2026-08-28T13:26:53.777+00:00France, Spain inflation surge fully prices ECB September 25bp hikehttps://static.edwealth.ai/news/images/france-spain-inflation-surge-fully-prices-ecb-september-25bp-hike-20260828.pngFrance, Spain inflation surge fully prices ECB September 25bp hike https://edgen.dev.edgen.tech/news/post/retiring-in-canada-1350-rent-universal-care-tax-trade-offs2026-08-28T13:26:05.822Zdaily1Edgen Stocken2026-08-28T13:26:05.822+00:00Retiring in Canada: $1,350 Rent, Universal Care, Tax Trade-offshttps://static.edwealth.ai/news/images/retiring-in-canada-1350-rent-universal-care-tax-trade-offs-20260828.pngRetiring in Canada: $1,350 Rent, Universal Care, Tax Trade-offs https://edgen.dev.edgen.tech/news/post/proposed-50000-social-security-cap-reshapes-the-67-vs-70-decision2026-08-28T13:22:47.640Zdaily1Edgen Stocken2026-08-28T13:22:47.640+00:00Proposed $50,000 Social Security cap reshapes the 67-vs-70 decisionhttps://static.edwealth.ai/news/images/proposed-50000-social-security-cap-reshapes-the-67-vs-70-decision-20260828.pngProposed $50,000 Social Security cap reshapes the 67-vs-70 decision https://edgen.dev.edgen.tech/news/post/near-retirees-max-out-23500-401k-in-final-5-year-push2026-08-28T13:20:54.040Zdaily1Edgen Stocken2026-08-28T13:20:54.040+00:00Near-Retirees Max Out $23,500 401(k) in Final 5-Year Pushhttps://static.edwealth.ai/news/images/near-retirees-max-out-23500-401k-in-final-5-year-push-20260828.pngNear-Retirees Max Out $23,500 401(k) in Final 5-Year Push https://edgen.dev.edgen.tech/news/post/a16z-launches-machine-age-fund-after-130m-hebbia-ai-bet2026-08-28T13:20:06.374Zdaily1Edgen Stocken2026-08-28T13:20:06.374+00:00a16z launches Machine Age fund after $130M Hebbia AI bethttps://static.edwealth.ai/news/images/a16z-launches-machine-age-fund-after-130m-hebbia-ai-bet-20260828.pnga16z launches Machine Age fund after $130M Hebbia AI bet https://edgen.dev.edgen.tech/news/post/tesla-stock-drops-21-as-five-year-sp-500-lag-persists2026-08-28T13:07:50.334Zdaily1Edgen Stocken2026-08-28T13:07:50.334+00:00Tesla stock drops 21% as five-year S&P 500 lag persistshttps://static.edwealth.ai/news/images/tesla-stock-drops-21-as-five-year-sp-500-lag-persists-20260828.pngTesla stock drops 21% as five-year S&P 500 lag persists https://edgen.dev.edgen.tech/news/post/novavax-nuvaxovid-secures-3-market-approvals-as-protein-vaccine-gains-ground2026-08-28T13:06:15.922Zdaily1Edgen Stocken2026-08-28T13:06:15.922+00:00Novavax Nuvaxovid secures 3-market approvals as protein vaccine gains groundhttps://static.edwealth.ai/news/images/novavax-nuvaxovid-secures-3-market-approvals-as-protein-vaccine-gains-ground-20260828.pngNovavax Nuvaxovid secures 3-market approvals as protein vaccine gains ground https://edgen.dev.edgen.tech/news/post/biotechs-85-rally-faces-chinas-fast-follower-drug-threat2026-08-28T13:04:33.630Zdaily1Edgen Stocken2026-08-28T13:04:33.630+00:00Biotech's 85% rally faces China's fast-follower drug threathttps://static.edwealth.ai/news/images/biotechs-85-rally-faces-chinas-fast-follower-drug-threat-20260828.pngBiotech's 85% rally faces China's fast-follower drug threat https://edgen.dev.edgen.tech/news/post/japans-record-154-trillion-yen-intervention-fades-as-fundamentals-bite2026-08-28T13:01:51.443Zdaily1Edgen Stocken2026-08-28T13:01:51.443+00:00Japan's Record ¥15.4 Trillion Yen Intervention Fades as Fundamentals Bitehttps://static.edwealth.ai/news/images/japans-record-154-trillion-yen-intervention-fades-as-fundamentals-bite-20260828.pngJapan's Record ¥15.4 Trillion Yen Intervention Fades as Fundamentals Bite https://edgen.dev.edgen.tech/news/post/yen-intervention-fades-japan-equities-hold-as-currency-sits-20-undervalued2026-08-28T13:01:08.057Zdaily1Edgen Stocken2026-08-28T13:01:08.057+00:00Yen Intervention Fades, Japan Equities Hold as Currency Sits 20% Undervaluedhttps://static.edwealth.ai/news/images/yen-intervention-fades-japan-equities-hold-as-currency-sits-20-undervalued-20260828.pngYen Intervention Fades, Japan Equities Hold as Currency Sits 20% Undervalued https://edgen.dev.edgen.tech/news/post/insulet-investors-face-aug-31-lead-plaintiff-deadline-in-class-action2026-08-28T12:58:09.083Zdaily1Edgen Stocken2026-08-28T12:58:09.083+00:00Insulet investors face Aug. 31 lead plaintiff deadline in class actionhttps://static.edwealth.ai/news/images/insulet-investors-face-aug-31-lead-plaintiff-deadline-in-class-action-20260828.pngInsulet investors face Aug. 31 lead plaintiff deadline in class action https://edgen.dev.edgen.tech/news/post/koreas-135-trillion-pension-fund-posts-record-27-return2026-08-28T12:50:42.667Zdaily1Edgen Stocken2026-08-28T12:50:42.667+00:00Korea's $1.35 trillion pension fund posts record 27% returnhttps://static.edwealth.ai/news/images/koreas-135-trillion-pension-fund-posts-record-27-return-20260828.pngKorea's $1.35 trillion pension fund posts record 27% return https://edgen.dev.edgen.tech/news/post/kazia-therapeutics-prices-40-million-offering-to-fund-breast-cancer-trials2026-08-28T12:49:25.868Zdaily1Edgen Stocken2026-08-28T12:49:25.868+00:00Kazia Therapeutics prices $40 million offering to fund breast cancer trialshttps://static.edwealth.ai/news/images/kazia-therapeutics-prices-40-million-offering-to-fund-breast-cancer-trials-20260828.pngKazia Therapeutics prices $40 million offering to fund breast cancer trials https://edgen.dev.edgen.tech/news/post/japans-record-987-billion-yen-rescue-echoes-1997-crisis2026-08-28T12:45:42.458Zdaily1Edgen Stocken2026-08-28T12:45:42.458+00:00Japan's record $98.7 billion yen rescue echoes 1997 crisishttps://static.edwealth.ai/news/images/japans-record-987-billion-yen-rescue-echoes-1997-crisis-20260828.pngJapan's record $98.7 billion yen rescue echoes 1997 crisis https://edgen.dev.edgen.tech/news/post/byd-h1-profit-drops-205-to-rmb123b-on-china-price-war2026-08-28T12:40:42.497Zdaily1Edgen Stocken2026-08-28T12:40:42.497+00:00BYD H1 profit drops 20.5% to RMB12.3B on China price warhttps://static.edwealth.ai/news/images/byd-h1-profit-drops-205-to-rmb123b-on-china-price-war-20260828.pngBYD H1 profit drops 20.5% to RMB12.3B on China price war https://edgen.dev.edgen.tech/news/post/biocryst-eyes-rare-disease-deals-with-645m-orladeyo-engine2026-08-28T12:40:04.146Zdaily1Edgen Stocken2026-08-28T12:40:04.146+00:00BioCryst eyes rare disease deals with $645M Orladeyo enginehttps://static.edwealth.ai/news/images/biocryst-eyes-rare-disease-deals-with-645m-orladeyo-engine-20260828.pngBioCryst eyes rare disease deals with $645M Orladeyo engine